Phathom Pharmaceuticals (PHAT)
US Market

Phathom Pharmaceuticals (PHAT) Stock Price & Analysis


PHAT Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$5.84 - $16.07
Previous Close$7.31
Average Volume (3M)427.34K
Market Cap
Enterprise Value$248.51M
Total Cash (Recent Filing)$155.38M
Total Debt (Recent Filing)$97.07M
Price to Earnings (P/E)-1.4
May 09, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.05
Shares Outstanding41,973,271
10 Day Avg. Volume351,850
30 Day Avg. Volume427,344
Standard Deviation0.17
Financial Highlights & Ratios
Price to Book (P/B)-3.47
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-1.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.46
Price Target Upside250.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5



Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Phathom Pharmaceuticals’s price range in the past 12 months?
Phathom Pharmaceuticals lowest stock price was $5.84 and its highest was $16.07 in the past 12 months.
    What is Phathom Pharmaceuticals’s market cap?
    Currently, no data Available
    When is Phathom Pharmaceuticals’s upcoming earnings report date?
    Phathom Pharmaceuticals’s upcoming earnings report date is May 09, 2023 which is in 39 days.
      How were Phathom Pharmaceuticals’s earnings last quarter?
      Phathom Pharmaceuticals released its earnings results on Feb 28, 2023. The company reported -$1.33 earnings per share for the quarter, beating the consensus estimate of -$1.351 by $0.021.
        Is Phathom Pharmaceuticals overvalued?
        According to Wall Street analysts Phathom Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Phathom Pharmaceuticals pay dividends?
          Phathom Pharmaceuticals does not currently pay dividends.
          What is Phathom Pharmaceuticals’s EPS estimate?
          Phathom Pharmaceuticals’s EPS estimate is -$1.26.
            How many shares outstanding does Phathom Pharmaceuticals have?
            Phathom Pharmaceuticals has 41,973,270 shares outstanding.
              What happened to Phathom Pharmaceuticals’s price movement after its last earnings report?
              Phathom Pharmaceuticals reported an EPS of -$1.33 in its last earnings report, beating expectations of -$1.351. Following the earnings report the stock price went down -11.753%.
                Which hedge fund is a major shareholder of Phathom Pharmaceuticals?
                Among the largest hedge funds holding Phathom Pharmaceuticals’s share is Gilder Gagnon Howe & Co LLC.. It holds Phathom Pharmaceuticals’s shares valued at 6M.


                  Phathom Pharmaceuticals Stock Smart Score

                  The Phathom Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Phathom Pharmaceuticals

                  Phathom Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. It develops Vonoprazan, a potassium-competitive acid blocker. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Buffalo Grove, IL.


                  Top 5 ETFs holding PHAT

                  Market Value
                  Smart Score
                  iShares Core S&P Total U.S. Stock Market ETF
                  Schwab U.S. Broad Market ETF
                  Up to five ETFs with an Outperform Smart Score that hold PHAT. The ETFs are listed according to market value of PHAT within the ETF


                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Rani Therapeutics Holdings
                  Nuvation Bio
                  Atea Pharmaceuticals

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis